At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed pancreatic adenocarcinoma
- ✓Measurable disease by RECIST 1.1
- ✓Documented objective radiographic progression after first-line therapy
- ✓Newly obtained or archived tumor tissue biopsy within 6 weeks prior to treatment
- ✕Non-adenocarcinoma pancreatic tumors (acinar cell, pancreaticoblastoma, endocrine, squamous cell, etc.)
- ✕Prior immunotherapy targeting PD-1, PD-L1, PD-L2, CTLA-4, OX-40, or CD-137
- ✕Radiographically detectable CNS metastases or carcinomatous meningitis
- ✕Active autoimmune disease requiring systemic treatment in past 2 years
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIb Pilot Study to Assess the Efficacy, Safety, and Pharmacodynamics Effects of Pembrolizumab and BL-8040 in Patients With Metastatic Pancreatic Cancer
In Brief
A Phase 2 clinical trial evaluating CXCR4 Antagonist BL-8040, Pembrolizumab, and 1 other intervention for Metastatic Pancreatic Adenocarcinoma and 2 related conditions. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This pilot phase IIb trial studies how well pembrolizumab and CXCR4 antagonist BL-8040 work in treating patients with pancreatic cancer that has spread to other places. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. CXCR4 antagonist BL-8040 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and CXCR4 antagonist BL-8040 may work better in treating patients with pancreatic cancer.
Study Details
Timeline
Interventions
Given SC
Given IV
Correlative studies